CNA Diagnostics secures new financing

Photo of author

By Ted Liu

CNA Diagnostics Inc. has closed a new round of financing, raising $[mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT – where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. Be informed!#[/mepr-active][mepr-active rule=”374″]1,172,274.50 from 27 investors through the issuance of 2,344,549 Class A common shares at $0.50 per share. The company raised $769,475 from 21 Alberta investors, $340,000 from 4 Ontario investors with remaining amount from one USA and one Austria investor. Shea Nerland LLP acted as legal counsel to CNA Diagnostics. [/mepr-active]

Calgary based CNA Diagnostics Inc. (CNAD) is a Molecular Diagnostics company developing disruptive diagnostic tests for a wide spectrum of complex diseases affecting people, pets and production animals. The company plans to commercialize high-sensitivity and specificity, molecular diagnostic technologies for subclinical detection of major diseases of food producing animals, companion animal and humans.

In June 2017, CNA Diagnostics and its German partners Metabion GmbH and Becker & Hickl GmbH were awarded CDN $800,000 from the Alberta and German governments to pursue development of a high throughput, rapid testing diagnostic machine.

photo credit: CNA Diagnostics Inc.